As in-vitro experiments suggested that blocking the extracellular domain of EGFR by Cetuximab is not sufficient to suppress tumor growth, Cetuximab might elicit antibody-dependent cell-mediated cytotoxicity (ADCC) or complement dependent cytotoxicity (CDC) in vivo [24], the latter may led to the inhibition of tumor xenograft in T cell-defective nude mice observed in this study. Here, EGFR is linked to neoplasm.